Bausch Health Companies Inc. (NYSE:BHC – Get Rating) was the recipient of some unusual options trading on Thursday. Traders purchased 28,075 call options on the stock. This is an increase of 45% compared to the typical daily volume of 19,298 call options.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on shares of Bausch Health Companies in a research report on Thursday. They set a “hold” rating for the company. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, Bausch Health Companies currently has an average rating of “Hold” and an average price target of $8.67.
Institutional Trading of Bausch Health Companies
A number of hedge funds and other institutional investors have recently modified their holdings of the company. National Bank of Canada FI raised its holdings in Bausch Health Companies by 12,687.5% during the fourth quarter. National Bank of Canada FI now owns 13,136,603 shares of the company’s stock valued at $82,497,000 after acquiring an additional 13,033,873 shares during the period. Natixis boosted its position in shares of Bausch Health Companies by 97.7% during the fourth quarter. Natixis now owns 15,817,975 shares of the company’s stock worth $99,337,000 after acquiring an additional 7,817,975 shares during the last quarter. Mizuho Markets Cayman LP purchased a new position in Bausch Health Companies during the first quarter valued at $56,700,000. Mizuho Markets Americas LLC purchased a new position in Bausch Health Companies during the first quarter valued at $56,700,000. Finally, ING Groep NV lifted its stake in Bausch Health Companies by 341.1% in the 4th quarter. ING Groep NV now owns 8,821,000 shares of the company’s stock worth $55,396,000 after purchasing an additional 6,821,000 shares in the last quarter. 66.99% of the stock is owned by hedge funds and other institutional investors.
Bausch Health Companies Price Performance
Bausch Health Companies (NYSE:BHC – Get Rating) last posted its quarterly earnings data on Thursday, February 23rd. The company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.92 by $0.10. The firm had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.12 billion. Bausch Health Companies had a positive return on equity of 381.67% and a negative net margin of 4.38%. Equities research analysts anticipate that Bausch Health Companies will post 3.34 earnings per share for the current year.
About Bausch Health Companies
Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb.
- Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.